Business Combinations - Additional Information (Detail) - USD ($)					1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 11, 2025	Feb. 03, 2025	Oct. 03, 2023	Mar. 08, 2023	Dec. 31, 2024	Feb. 29, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Business Acquisition [Line Items]
Goodwill					$ 73,343,000		$ 325,793,000		$ 325,793,000
Tax benefit from release of a portion of valuation allowance attributable to estimated deferred tax liabilities							(212,000)	$ (95,000)	45,968,000	$ (106,000)
Net revenue							314,635,000	165,969,000	570,372,000	311,789,000
Net (loss) income							(42,843,000)	(552,212,000)	(110,880,000)	(616,955,000)
Payment to acquire business net of cash acquired									380,762,000	0
Maximum [Member]
Business Acquisition [Line Items]
Tax benefit from release of a portion of valuation allowance attributable to estimated deferred tax liabilities							(200,000)		46,000,000
Genomics Product [Member]
Business Acquisition [Line Items]
Net revenue							241,800,000	$ 112,300,000	435,600,000	$ 214,900,000
Ambry [Member]
Business Acquisition [Line Items]
Goodwill		$ 231,186,000
Business combination aggregate consideration transferred		695,343,000
Payments to acquire businesses, gross		397,296,000
Base cash consideration		375,000,000
Business combination consideration transferred equity interests issued and issuable		298,047,000
Amount owed to acquiree under preexisting relationship		3,800,000
Transaction costs							7,200,000		7,200,000
Acquisition-related costs							1,500,000		4,500,000
Goodwill, expected to be deductible for tax purposes		$ 600,000
Tax benefit from release of a portion of valuation allowance attributable to estimated deferred tax liabilities							(46,200,000)
Net (loss) income							2,200,000		7,700,000
Ambry [Member] | Securities Purchase Agreement [Member]
Business Acquisition [Line Items]
Business acquisition equity interests issued or issuable number of shares issued		4,843,136
Ambry [Member] | Common Class A [Member] | Securities Purchase Agreement [Member]
Business Acquisition [Line Items]
Class A common stock, closing price		$ 61.54
Stock issued during period number of shares subject to lock in period		2,152,505
Ambry [Member] | Genomics Product [Member]
Business Acquisition [Line Items]
Net revenue							$ 97,300,000		160,800,000
Deep 6 [Member]
Business Acquisition [Line Items]
Goodwill	$ 21,100,000
Business combination aggregate consideration transferred	17,400,000
Payments to acquire businesses, gross	4,300,000
Business combination consideration in the form of shares held back	800,000
Deep 6 [Member] | Other Current Liabilities [Member]
Business Acquisition [Line Items]
Business combination consideration in the form of shares held back	800,000
Deep 6 [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Business combination consideration transferred equity interests issued and issuable	$ 13,100,000
Sengine [Member]
Business Acquisition [Line Items]
Goodwill			$ 9,600,000
Business combination aggregate consideration transferred			9,900,000						$ 0
Payments to acquire businesses, gross			2,800,000
Business combination consideration in the form of shares held back			1,400,000
Sengine [Member] | Maximum [Member]
Business Acquisition [Line Items]
Net working capital adjustment			100,000
Sengine [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Business combination consideration transferred equity interests issued and issuable			$ 6,300,000
Business acquisition equity interests issued or issuable number of shares issued			35,000
Stock issued during the period shares towards working capital adjustment						429
Sengine [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Business acquisition equity interests issued or issuable number of shares issued					19,620
Mpirik [Member]
Business Acquisition [Line Items]
Goodwill				$ 10,600,000
Business combination aggregate consideration transferred				9,700,000
Business combination consideration transferred equity interests issued and issuable				4,600,000
Business combination consideration in the form of shares held back				300,000
Business combination aggregate cash consideration payable including the amount witheld				4,700,000
Business combination contingent consideration payable in cash at fair value				400,000
Business combination cash consideration held back				$ 800,000
Mpirik [Member] | Nonvoting Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during the period shares in respect of consideration held back				8,724